Needham Reiterates Buy on Verrica Pharmaceuticals, Maintains $8 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham has reiterated its Buy rating on Verrica Pharmaceuticals (NASDAQ:VRCA) and maintained its $8 price target for the company's stock.
April 10, 2024 | 10:58 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham has reaffirmed its Buy rating and $8 price target for Verrica Pharmaceuticals, indicating a positive outlook on the company's stock.
The reiteration of a Buy rating and maintenance of a price target by a reputable analyst firm like Needham can have a positive impact on investor sentiment towards VRCA. This endorsement suggests confidence in the company's future performance and potential for stock price appreciation.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100